Long-term Efficacy and Safety of Inotersen for Hereditary Transthyretin Amyloidosis: NEURO-TTR Open-Label Extension 3-Year Update
Journal of neurology(2022)
Key words
Clinical trial,Familial amyloid polyneuropathy,Inotersen,Hereditary transthyretin amyloidosis,Peripheral neuropathies,Polyneuropathy
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined